| Similar Articles |
|---|
 |
Bio-IT World
February 18, 2004 |
On the Up and Up Market values for biotec companies increase as they deal and deliver in the fourth quarter   |
Bio-IT World
May 19, 2004
Branca, Hoffer & Nambiar |
Keeping an Even Keel Bland first quarter was punctuated by HGS mini-drama: Biotech guru Steven Burrill hailed the first quarter of 2004 as biotech's best funding quarter in the industry's 30-year history. But it was also a strange one. |
Bio-IT World
November 19, 2004
Hoffer & Nambiar |
Mirus Index Heads South Overall, companies in the Mirus Index declined in the third quarter of 2004. |
Bio-IT World
August 13, 2003
Branca et al. |
Discovery Surges and Tools Deliver Market Compass for Q2 finds consolidation among drug discovery companies continuing, but market caps rising. |
Bio-IT World
August 18, 2004 |
Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated. |
Bio-IT World
January 13, 2003
Malorye Branca |
Charting a Course After the Genome A quarterly feature looks at the financial numbers in the bio-IT industry. |
Bio-IT World
May 9, 2003
Malorye Branca |
Discovering the Joy of Cannibalism Persistent financial pressures feed continuing consolidation among struggling genomics companies |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
April 18, 2006
Tom Taulli |
An ETF for New Stocks IPOs become the latest to join the ETF party. The IPOX-100 Index Fund is essentially a mid-cap index -- with a nice marketing angle. |
Bio-IT World
January 12, 2004
Kevin Davies |
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
May 2006
G. Steven Burrill |
Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
Financial Planning
June 1, 2008
Arnott et al. |
Heads I Win, Tails I Lose Less A Fundamental Index portfolio is neutral relative to the economy, weighting companies in accordance with their current economic footprint. When is it the right choice for investors? |
Bio-IT World
March 2006 |
Special Show Preview: It's Showtime! Highlights of the upcoming fifth annual Bio IT World conference: Decoding the Genome... The Six-Figure Sequence... E-Clinical Futures... etc. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
The Motley Fool
February 27, 2009
Brian Orelli |
Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
September 2005
Mark D. Uehling |
Kings of Genes and Data The speed by which things move at Iceland's deCODE supports the company's claim that it is not only reconnecting the bifurcated worlds of drug discovery and clinical research - it is also internally cross-pollinating ideas between those two realms. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
December 30, 2003
Tom Taulli |
M&A As Strong Medicine Invitrogen's latest deal shows that the company knows where its market is headed. |
The Motley Fool
February 28, 2007
Brian Lawler |
Discovery Prepares for Its Fate Discovery Labs announces its quarterly financial results as it prepares for another meeting with the FDA. Investors, take note. |
The Motley Fool
April 6, 2011
MIchael Johnston |
AAPL Weighting in QQQ to Be Slashed What does the change mean for the ETF? |
Bio-IT World
August 2005
G. Steven Burrill |
Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
The Motley Fool
August 14, 2007
Brian Orelli |
Drugmaker Growth Without the FDA Do you have one of those stomachs that just can't take the ups and downs of clinical trial data and FDA approval decisions? Buy stocks in the companies that support the drug makers. |
Information Today
May 9, 2013 |
BioOne Online Journals Now Searchable Via EBSCO Discovery Service EBSCO Discovery Service users are able to search more than 100,000 scholarly articles from bioscience research journals in the Base Index of EBSCO Discovery Service. |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
The Motley Fool
November 15, 2006
Alyce Lomax |
A Very Complicated Discovery Complexity rules in Discovery Holding's third-quarter results. Investors, take note. |
Bio-IT World
January 13, 2003
Kari Stefansson |
The Icelandic Man Cometh The founder of deCODE Genetics on Viking DNA, privacy, disease, and aging. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
The Motley Fool
December 5, 2005
W.D. Crotty |
Rigel Pharmaceuticals Gets Stomped The biotech tumbles on poor phase 2 trial results for an allergy drug. Until another compound begins to offer glimmers of hope, this stock will probably offer little if any price appreciation. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
Bio-IT World
November 12, 2002
Debra Goldfarb |
Disruption --The Real Revolution What is the real promise of the genomic revolution? It is its power to unleash disruptive innovation -- technology that allows a new group of people with different skill sets to do things in a decentralized, less expensive way. |
BusinessWeek
January 12, 2004 |
Biotech: A Comeback "Balanced On A Razor's Edge" Skeptical investors want to see products that get to market and add to the bottom line. |
The Motley Fool
April 4, 2005
John Reeves |
Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier. |
Information Today
July 15, 2010 |
Web of Science Searchable in EBSCO Discovery Service Institutions subscribing to both EDS and Web of Science may conduct their searches via the single search box of EBSCO Discovery Service, access the content in Web of Science within the results, and be able to link over to the full Web of Science record. |
Bio-IT World
March 8, 2005 |
Coming Attractions Ten reasons why you can't miss the Bio*IT World Conference + Expo in May. Headlines and Legends... Advances in Genomic Medicine... IT Solutions for Drug Discovery... etc. |
Financial Advisor
December 2004
Christopher P. Parr |
Look Mom! I Beat the S&P Again! Legg's Value Trust---relative fund superstar or absolute media hype? |
Financial Planning
June 1, 2009
Richard A. Ferri |
Mapping Indexes Today's advisors can best serve their clients with a working knowledge of the various index methodologies. Unfortunately, this is no easy task. |
Bio-IT World
October 14, 2004
Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
IndustryWeek
April 9, 2003
John S. McClenahen |
Surprise: Manufacturing Business Outlook Index Expands In March But quarterly measure by Manufacturers Alliance/MAPI dips below December's five-year high. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
IndustryWeek
October 6, 2004
John S. McClenahen |
Manufacturers Alliance Index Eases Off Record Pace U.S. manufacturing's recovery from the 2001 recession is likely to continue during the next three to six months, but at a somewhat slower pace than has recently occurred. But data suggest broad-based expansion is likely to continue. |
